Could early treatment stop asthma before it gets severe?

NCT ID NCT07309614

Recruiting now Disease control Sponsor: Université de Sherbrooke Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the medication dupilumab can help people with moderate asthma achieve complete control (remission) when given early, before the disease becomes severe. About 150 adults aged 18-79 with moderate asthma and high inflammation markers will receive either dupilumab or a placebo every 2 weeks for one year, alongside their usual inhalers. The goal is to see if early treatment prevents asthma attacks and lung damage, potentially changing the approach from waiting until asthma is severe to preventing it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA CONTROL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA CONTROL

Contacts and locations

Locations

CIUSSS de l'Estrie- CHUS
RECRUITING

Sherbrooke, Quebec, J1H 5H6, Canada
Institut universitaire de cardiologie et de pneumologie de Québec
NOT_YET_RECRUITING

Québec, Quebec, G1V 4G5, Canada
McGill University Health Centre
NOT_YET_RECRUITING

Montreal, Quebec, H4A 3S5, Canada
Oxford University Hospitals NHS Foundation Trust - John Radcliffe Hospital
NOT_YET_RECRUITING

Oxford, Oxfordshire, OX3 9DU, United Kingdom
Sir Charles Gairdner Hospital
NOT_YET_RECRUITING

Nedlands, Western Australia, 6009, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.